The University of Oregon and mAbDx have finalized a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products. CTIP2 (also known as BCL11b) is a zinc finger transcription factor essential for transcriptional control of hundreds of genes encoding key proteins in cell signaling pathways during …
read moremAbDx and MitoSciences/Abcam sign Master Project Agreement
mAbDx and MitoSciences/Abcam sign Master Project Agreement for mAbDx to develop medical/clinical diagnostics for: 1) sepsis, 2) SIRS (Systemic Inflammatory Response Syndrome), 3) HNSCC (Head and Neck Squamous Cell Carcinoma), 4) preeclampsia, and 5) inherited diseases affecting mitochondrial OXPHOS complexes I and IV.
read moremAbDx and University of Oregon Sign Agreement to Support mAbDx monoclonal antibody Development
mAbDx and the University of Oregon sign a space and care agreement to support mAbDx development of monoclonal antibodies and assays to identify and study mitochondrial DAMPs.
read moremAbDx Moves Laboratory to University of Oregon Innovation Center
mAbDx moves into new laboratory space in the Innovation Center at the University of Oregon Riverfront Research Park.
read moremAbDx Granted Approval for Development of Monoclonal Antibodies
mAbDx granted IACUC approval for the development of monoclonal antibodies and immunoassays to identify and study mitochondrial DAMPs. Project title: “Defining the contribution of mitochondrial damage-associated-molecular patterns (mtDAMPs) to the systemic inflammatory response syndrome (SIRS) after tissue injury”.
read more